Navigation Links
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Date:10/25/2011

rder Therapeutic Market, SWOT Analysis of Johnson & Johnson, 2010 202

Figure 108: CNS Disorder Therapeutic Market, SWOT Analysis of Teva 203

Figure 109: CNS Disorder Therapeutic Market, Global M&A Deals by Region, 2010-2011 204

Figure 110: CNS Disorder Therapeutic Market, Global M&A Deals by Indication, 2010-2011 205

Figure 111: CNS Disorder Therapeutic Market, Global, M&A Deals by Value ($m), 2010-2011 206

Figure 112: CNS Disorder Therapeutic Market, Licensing Deals, by Indication, 2010-2011 212

Figure 113: CNS Disorder Therapeutic Market, Co-developments by Indication, 2010-2011 218

Figure 114: GBI Research Market Forecasting Model 228

Companies Mentioned

Eli Lilly

Pfizer

AstraZeneca

Johnson & Johnson (J&J)

Teva

To order this report:

Pathology Industry: Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders
2. South and Central America Cardiovascular Devices Market Outlook to 2017
3. Carolinas HealthCare System (CHS) Contributes to First Childrens Burn Hospital in Central America
4. Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011
5. United Seating & Mobility Reaches Agreement to Acquire Central Kentucky Mobility
6. Reportlinker Adds South and Central America Dental Devices Market Outlook to 2017
7. Reportlinker Adds South and Central America Drug Delivery Devices Market Outlook to 2017
8. Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
9. Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
10. Reportlinker Adds Drug Delivery Devices Market Outlook in Russian Federation to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
11. Reportlinker Adds Drug Delivery Devices Market Outlook in China to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... Now Approved with Four Indications for Five-Day Regimen, ... Food and Drug,Administration (FDA) has approved use of ... I.V. and oral, for the treatment of,complicated urinary ... This latest approval is based on results of ...
... The way the government keeps our,medicines ... goes through.,Those changes were the subject of ... Listen to this report from Pfizer at:, ... video, audio, text, graphics and,photos for free ...
... BKD ) announced today that its Board of ... stock of $0.50 per share for the,quarter ending September ... October 12, 2007 to holders of record of Brookdale,s ... Inc. is a leading owner and operator of senior,living ...
... VANCOUVER, Sept. 17 /PRNewswire-FirstCall/ - Cardiome Pharma ... Chairman and Chief,Executive Officer, will present an overview ... in San Francisco at 8:00am Pacific Time,(11:00am Eastern ... live webcast of Mr. Rieder,s presentation can be ...
... Million People Nationwide to take 10 Billion, Steps and ... WASHINGTON, Sept. 17 More than 1,500 YMCAs nationwide,will ... living and,healthy eating during "America On the Move Week ... with the America On the Move,Foundation, aims to educate ...
... Company,s Executive Team, VIRGINIA BEACH, Va., Sept. ... announced that Mary McCluskey, MD, has been,named Chief ... 1.5 million members. "We are excited to ... AMERIGROUP President and Chief Executive Officer. "Throughout her,career, ...
Cached Medicine News:Health News:FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis 2Health News:FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis 3Health News:FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis 4Health News:Cardiome to Present at ThinkEquity Conference 2Health News:Cardiome to Present at ThinkEquity Conference 3Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 2Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 3Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 4Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 5Health News:AMERIGROUP Names Mary McCluskey, MD, Chief Medical Officer 2Health News:AMERIGROUP Names Mary McCluskey, MD, Chief Medical Officer 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: